Mitochondrial neurogastrointestinal encephalopathy (MNGIE) is a multisystem, autosomal recessive disorder characterized by ptosis, progressive external ophthalmoplegia, gastroparesis cachexia, peripheral neuropathy, and diffuse leukoencephalopathy. MNGIE is rare and the prevalence is unknown, however, to date there have been 76 mutations reported in the TYMP gene associated with MNGIE. We report two novel mutations that have not been previously described in a patient with clinical MNGIE syndrome.
introduction
Mitochondrial neurogastrointestinal encephalopathy (MNGIE) is a multisystem, autosomal recessive disorder characterized by ptosis, progressive external ophthalmoplegia, gastroparesis, cachexia, peripheral neuropathy, and diffuse leukoencephalopathy [1] . It is caused by mutations in the TYMP gene encoding thymidine phosphorylase (TP) located on chromosome 22q13.33 [1, 6] . This enzyme catalyzes the nucleosides thymidine and deoxyuridine to thymine and uridine respectively. It has been postulated that the accumulation of these nucleosides (thymidine and deoxyuridine) leads to mitochondrial DNA instability [2] , hence the multisystem Since the affected enzyme is known, further work is needed in the various treatment methods including enzyme replacement therapy.
